Economic Evaluation in Genomic Medicine

Economic Evaluation in Genomic Medicine

Volumn , Issue , 2015, Pages 1-163

  Fragoulakis, Vasilios ^a,b   Mitropoulou, Christina ^c   Williams, Marc S ^d   Patrinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926494040     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2013-0-23169-X     Document Type: Book

References (271)

1. D. Banta (2003) The development of health technology assessment. Health Policy 63(2), 121-132.
2. J.T. Braslow (1999) History and evidence-based medicine: lessons from the history of somatic treatments from the 1900s to the 1950s. Ment. Health Serv. Res. 1(4), 231-240.
3. J.A. Claridge and T.C. Fabian (2005) History and development of evidence-based medicine. World J. Surg. 29(5), 547-553.
4. L. Cohen (1996) McMaster’s pioneer in evidence-based medicine now spreading his message in England. Can. Med. Assoc. J. 154(3), 388-390.
5. J.A. Hadley, J. Davis and K.S. Khan (2007) Teaching and learning evidence-based medicine in complementary, allied, and alternative health care: an integrated tailor-made course. J. Altern Complement Med. 13(10), 1151-1155.
6. R.L. Sur and P. Dahm (2011) History of evidence-based medicine. Ind. J. Urol. 27(4), 487-489.
7. J. Van Den Bos, K. Rustagi, T. Gray, M. Halford, E. Ziemkiewicz and J. Shreve (2011) The $17.1 billion problem: the annual cost of measurable medical errors. Health Aff. (Millwood) 30(4), 596-603.
8. M.S. Williams (2014) Genomic medicine implementation: learning by example. Am. J. Med. Genet. C Semin. Med. Genet. 166 8-14.
9. E. Abrahams, G.S. Ginsburg and M. Silver (2005) The personalized medicine coalition: goals and strategies. Am. J. Pharmacogenomics 5 345-355.
10. M. Alda (2013) Personalized psychiatry: many questions, fewer answers. J. Psychiatry Neurosci. 38 363-365.
11. M.J. Arranz and J. de Leon (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12 707-747.
12. A.O. Berg, K. Armstrong, J. Botkin, N. Calonge, J. Haddow, M. Hayes, et al. (2009) Recommendations from the EGAPP working group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11(1), 15-20.
13. L. Bodin, C. Verstuyft, D.A. Tregouet, A. Robert, L. Dubert, C. Funck-Brentano, et al. (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 135-140.
14. S. Bota, I. Sporea, R. Şirli, A.M. Neghină, A. Popescu and M. Străin (2013) Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin. Drug Investig. 33(5), 325-331.
15. J.J. Carlson, L.P. Garrison, S.D. Ramsey and D.L. Veenstra (2009) The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12 20-27.
16. L. Chouchana, C. Narjoz, P. Beaune, M.A. Loriot and X. Roblin (2012) Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 35(1), 15-36.
17. D.N. Cooper, A. Brand, V. Dolzan, P. Fortina, F. Innocenti, M.T. Lee, et al. (2014) Bridging genomics research between developed and developing countries: the genomic medicine alliance. Pers Med. 11 615-623.
18. P.A. Deverka and H.L. McLeod (2008) Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin. Pharmacol. Ther. 84 191-193.
19. P.A. Deverka, J. Vernon and H.L. McLeod (2010) Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50 423-437.
20. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2007) Recommendations from the EGAPP working group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med. 9(12), 819-825.
21. C.R. Flowers and D. Veenstra (2004) The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22 481-493.
22. F.W. Frueh and D. Gurwitz (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5 571-579.
23. B.F. Gage, C. Eby, J.A. Johnson, E. Deych, M.J. Rieder, P.M. Ridker, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84 326-331.
24. T. Geisler, E. Schaeffele, J. Dippon, S. Winter, V. Buse, C. Bischofs, et al. (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9 1251-1259.
25. G.S. Ginsburg and H.F. Willard (2009) Genomic and personalized medicine: foundations and applications. Transl. Res. 154 277-287.
26. D.M. Girnita, G. Burckart and A. Zeevi (2008) Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Curr. Opin. Immunol. 20 614-625.
27. P. Gladding, M. Webster, J. Ormiston, S. Olsen and H. White (2008) Antiplatelet drug nonresponsiveness. Am. Heart J. 155 591-599.
28. D. Gurwitz, A. Weizman and M. Rehavi (2003) Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24 122-125.
29. Holtzman, N.A., Watson, M.S. (Eds.), 1997. Promoting safe and effective genetic testing in the United States. Final report of the task force on genetic testing. .
30. C.R. Huizenga, K. Lowstuter, K.C. Banks, V.I. Lagos, V.O. Vandergon and J.N. Weitzel (2010) Evolving perspectives on genetic discrimination in health insurance among health care providers. Fam. Cancer 9(2), 253-260.
31. A.M. Issa (2002) Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1 300-308.
32. K. Kampourakis, E. Vayena, C. Mitropoulou, J. Borg, R.H. van Schaik, D.N. Cooper, et al. (2014) Key challenges for next generation pharmacogenomics. EMBO Rep. 15(5), 472-476.
33. T.E. Klein, R.B. Altman, N. Eriksson, B.F. Gage, S.E. Kimmel, M.T. Lee, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360 753-764.
34. S.S. Lee and A. Mudaliar (2009) Medicine. Racing forward: the genomics and personalized medicine act. Science 323 342.
35. Y. Mai, T. Koromila, A. Sagia, D.N. Cooper, G. Vlachopoulos, G. Lagoumintzis, et al. (2011) A critical view of the general public’s awareness and physicians’ opinion of the trends and potential pitfalls of genetic testing in Greece. Pers. Med. 8 551-561.
36. Y. Mai, C. Mitropoulou, X.E. Papadopoulou, A. Vozikis, D.N. Cooper, R.H. van Schaik, et al. (2014) Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Pers. Med. 11(1), 15-26.
37. S. Mallal, et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358 568-579.
38. E.T. Matloff, H. Shappell, K. Brierley, B.A. Bernhardt, W. McKinnon and B.N. Peshkin (2000) What would you do? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J. Clin. Oncol. 18 2484-2492.
39. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360 354-362.
40. L. Mette, K. Mitropoulos, A. Vozikis and G.P. Patrinos (2012) Pharmacogenomics and public health: implementing populationalized medicine. Pharmacogenomics 13(7), 803-813.
41. K. Mitropoulos, L. Johnson, A. Vozikis and G.P. Patrinos (2011) Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol. Drug Interact. 26 143-146.
42. Mitropoulou, C., Mai, Y., van Schaik, R.H., Vozikis, A., Patrinos, G.P., 2015. Documentation and analysis of the policy environment and key stakeholders in pharmacogenomics and genomic medicine in Greece. Public Health Genomics 17, 280–286.
43. C. Mizzi, C. Mitropoulou, K. Mitropoulos, B. Peters, M.R. Agarwal, R.H. van Schaik, et al. (2014) Personalized pharmacogenomics profiling using whole genome sequencing. Pharmacogenomics 15(9), 1223-1234.
44. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, et al. (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 947-957.
45. D. Pacheu-Grau, A. Gomez-Duran, M.J. Lopez-Perez, J. Montoya and E. Ruiz-Pesini (2010) Mitochondrial pharmacogenomics: barcode for antibiotic therapy. Drug Discov. Today 15 33-39.
46. G.P. Patrinos (2010) General considerations for integrating pharmacogenomics into mainstream medical practice. Hum. Genomics 4 371-374.
47. S.G. Pauker and J.P. Kassirer (1987) Decision analysis. N. Engl. J. Med. 316(5), 250-258.
48. R.H. Perlis, J.W. Smoller, M.A. Ferreira, A. McQuillin, N. Bass, J. Lawrence, et al. (2009) A genome-wide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry 166 718-725.
49. R.H. Perlis, A. Patrick, J.W. Smoller and P.S. Wang (2009) When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34 2227-2236.
50. F.J. Picard and M.G. Bergeron (2002) Rapid molecular theranostics in infectious diseases. Drug Discov. Today 7 1092-1101.
51. B.L. Pierce and H. Ahsan (2010) Case-only genome-wide interaction study of disease risk, prognosis and treatment. Genet. Epidemiol. 34 7-15.
52. M. Piquette-Miller and D.M. Grant (2007) The art and science of personalized medicine. Clin. Pharmacol. Ther. 81 311-315.
53. M. Pirmohamed (2006) Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharmacol. 62 509-511.
54. C. Pisanu, E.E. Tsermpini, E. Mavroidi, T. Katsila, G.P. Patrinos and A. Squassina (2014) Assessment of the Pharmacogenomics Educational Environment in Southeast Europe. Public Health Genomics 17, 272, 279
55. G. Potamias, K. Lakiotaki, T. Katsila, M. Lee, S. Topouzis, D.N. Cooper, et al. (2014) Deciphering next-generation pharmacogenomics: an information technology perspective. OPEN Biol. 4(7), 140071.
56. V.L. Priest, E.J. Begg, S.J. Gardiner, C.M. Frampton, R.B. Gearry, M.L. Barclay, et al. (2006) Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24 767-781.
57. M.V. Relling, M.L. Hancock, G.K. Rivera, J.T. Sandlund, R.C. Ribeiro, E.Y. Krynetski, et al. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91 2001-2008.
58. T.A. Reydon, K. Kampourakis and G.P. Patrinos (2012) Genetics, genomics and society: the responsibilities of scientists for science communication and education. Pers. Med. 9 633-643.
59. J.A. Robertson (2001) Consent and privacy in pharmacogenetic testing. Nat. Genet. 28 207-209.
60. M.A. Rothstein and P.G. Epps (2001) Ethical and legal implications of pharmacogenomics. Nat. Rev. Genet. 2 228-231.
61. T. Schalekamp, B.P. Brassé, J.F. Roijers, E. van Meegen, F.J. van der Meer, E.M. van Wijk, et al. (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin. Pharmacol. Ther. 81 185-193.
62. A. Smart, P. Martin and M. Parker (2004) Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 18 322-342.
63. B.B. Spear, M. Heath-Chiozzi and J. Huff (2001) Clinical application of pharmacogenetics. Trends Mol. Med. 7 201-204.
64. A. Squassina, M. Manchia, V.G. Manolopoulos, M. Artac, C. Lappa-Manakou, S. Karkabouna, et al. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11 1149-1167.
65. A. Squassina, M. Manchia, J. Borg, D. Congiu, M. Costa, M. Georgitsi, et al. (2011) Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 12 1559-1569.
66. M. Stanulla, E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, et al. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293(12), 1485-1489.
67. M. Tamaoki, H. Gushima and K. Tsutani (2007) Awareness survey of parties involved in pharmacogenomics in Japan. Pharmacogenomics 8 275-286.
68. E.E. Tsermpini, K. Assimakopoulos, M. Bartsakoulia, G. Economou, E. Papadima, K. Mitropoulos, et al. (2014) Individualizing clozapine and risperidone treatment for schizophrenia patients. Pharmacogenomics 15(1), 95-110.
69. L.T. Vaszar, M.K. Cho and T.A. Raffin (2003) Privacy issues in personalized medicine. Pharmacogenomics 4 107-112.
70. M.S. Williams (2007) Insurance coverage for pharmacogenomic testing in the United States. Pers. Med. 4(4), 479-487.
71. A. Basu and D. Meltzer (2007) Value of information on preference heterogeneity and individualized care. Med. Decis. Making 27(2), 112-127.
72. J.A. Bock, K.J. Fairley, R.E. Smith, D.D. Maeng, J.M. Pitcavage, N.A. Inverso, et al. (2014) Cost-effectiveness of IL28 genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 17 306-319.
73. K.E. Caudle, T.E. Klein, J.M. Hoffman, D.J. Muller, M. Whirl-Carrillo, L. Gong, et al. (2014) Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr. Drug Metab. 15(2), 209-217.
74. D.A. Flockhart, D. O’Kane, M.S. Williams and M.S. Watson (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 10 139-150.
75. L.G. Gordon, G.C. Mayne, N.G. Hirst, T. Bright and D.C. Whiteman (2014) Australian cancer study clinical follow-up study, Watson DI. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest. Endosc. 79(2), 242-256.e6.
76. S.D. Grosse, S. Wordsworth and K. Payne (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet. Med. 10(9), 648-654.
77. R.R. Gullapalli, M. Lyons-Weiler, P. Petrosko, R. Dhir, M.J. Becich and W.A. LaFramboise (2012) Clinical integration of next-generation sequencing technology. Clin. Lab. Med. 32(4), 585-599.
78. H. Kilpinen and J.C. Barrett (2013) How next-generation sequencing is transforming complex disease genetics. Trends. Genet. 29(1), 23-30.
79. L.M. Meckley, J.M. Gudgeon, J.L. Anderson, M.S. Williams and D.L.A. Veenstra (2010) Policy model to evaluate the benefits, risks and costs of Warfarin pharmacogenomic testing. Pharmacoeconomics 28(1), 61-74.
80. D.A. Regier, J.M. Friedman, N. Makela, M. Ryan and C.A. Marra (2009) Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clin. Genet. 75(6), 514-521.
81. J.H. Rubenstein, N. Vakil and J.M. Inadomi (2005) The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 22(2), 135-146.
82. A. Squassina, M. Manchia, V.G. Manolopoulos, M. Artac, C. Lappa-Manakou, S. Karkabouna, et al. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11(8), 1149-1167.
83. F. Vogel (1959) Moderne probleme der humangenetik. Ergebn. Inn. Med. Kinderheilkd. 12 52-125.
84. J.A. Barber and A. Thompson (1998) Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ 317 1195-1200.
85. W.C. Black (1990) The CE plane: a graphic representation of cost-effectiveness. Med. Decis. Making 10 212-214.
86. A.H. Briggs and B.J. O’Brien (2001) The death of cost-minimization analysis? Health Econ. 10(2), 179-184.
87. Canning, D., 2009. Axiomatic foundations of cost effectiveness analysis. Working Paper Series. PGDA Working Paper No.51 .
88. S. Cantor (1994) Cost-effectiveness analysis, extended dominance, and ethics. A quantitative assessment. Med. Decis. Making 14 259-265.
89. C.F. Chiou, J.W. Hay, J.F. Wallace, B.S. Bloom, P.J. Neumann, S.D. Sullivan, et al. (2003) Development and validation of a grading system for the quality of cost-effectiveness studies. Med. Care 41(1), 32-44.
90. K. Claxton (1999) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J. Health Econ. 18(3), 341-364.
91. D. Collett (Ed.) (2003) Modelling Survival Data in Medical Research second ed. Boca Raton, FL: Chapman & Hall/CRC Press
92. A.S. Detsky and I.G. Naglie (1990) A clinician’s guide to cost-effectiveness analysis. Ann. Intern. Med. 113(2), 147-154.
93. M. Drummond, M. Sculpher and G. Torrance (2005) Methods for the Economic Evaluation of Health Care Programmes Oxford: Oxford University Press
94. B. Efron and R.J. Tibshirani (1993) An Introduction to the Bootstrap Boca Raton, FL: Chapman & Hall/CRC Press
95. EuroQol Group Association, EuroQol EQ-5D™. .
96. M.M. Goetghebeur and D. Rindress (1999) Towards a European consensus on conducting and reporting health economic evaluations—a report from the ISPOR inaugural European conference. Value Health 2 281-287.
97. A. Gray, P. Clarke and J. Wolstenholme (2011) Applied Methods of Cost-Effectiveness Analysis in Healthcare Oxford: Oxford University Press
98. G.C. Morrison (1998) Understanding the disparity between WTP and WTA: endowment effect, substitutability, or imprecise preferences? Econ. Lett. 59 189.
99. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal, March 2011. .
100. B.J. O’Brien and A. Gafni (1996) When do the dollars make sense? Toward a conceptual framework for contingent valuation studies in health care. Med. Decis. Making 16 288-299.
101. B.J. O’Brien, K. Gertsen, A.R. Willan and L.A. Faulkner (2002) Is there a kink in consumers’ threshold value for cost-effectiveness in health care? Health Econ. 11(2), 175-180.
102. J.J. Ofman, S.D. Sullivan, P.J. Neumann, C.F. Chiou, J.M. Henning, S.W. Wade, et al. (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9(1), 53-61.
103. S. Palmer and J. Raftery (1999) Opportunity cost. BMJ 318(7197), 1551-1552.
104. M.V. Pauly (1995) Valuing Health Care Benefits in Money Terms Cambridge: Cambridge University Press
105. S. Ramsey, R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla, et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health 8(5), 521-530.
106. R. Sullivan, J. Peppercorn, K. Sikora, et al. (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933-980.
107. G.W. Torrance (1986) Measurement of health state utilities for economic appraisals: a review. J. Health Econ. 5 1-30.
108. WHO guide to cost-effectiveness analysis, 2003. .
109. A. Willan and D.Y. Lin (2001) Incremental net benefit in randomized clinical trials. Stat. Med. 20 1563-1574.
110. K.J. Arrow (1963) Social Choice and Individual Values second ed. New York, NY: Wiley
111. G.R. Barton, A.H. Briggs and E.A. Fenwick (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11(5), 886-897.
112. A.H. Briggs and P. Fenn (1998) Confidence intervals or surfaces? uncertainty on the cost-effectiveness plane. Health Econ. 7 723-740.
113. P.G. Casali (2007) The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann. Oncol. 18(12), 1923-1925.
114. I.Y. Choi, T.M. Kim, M.S. Kim, S.K. Mun and Y.J. Chung (2013) Perspectives on clinical informatics: integrating large-scale clinical, genomic, and health information for clinical care. Genomics Inform. 11(4), 186-190.
115. M. Cialkowska, T. Adamowski, P. Piotrowski and A. Kiejna (2008) What is the Delphi method? Strengths and shortcomings. Psychiatr. Pol. 42(1), 5-15.
116. K. Claxton, M. Sculpher, C. McCabe, et al. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339-347.
117. B.J. Cohen (2003) Discounting in cost–utility analysis of healthcare interventions: reassessing current practice. Pharmacoeconomics 21(2), 75-87.
118. J.K. Daggy, J. Thomas III and B.A. Craig (2011) Modeling correlated healthcare costs. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 101-111.
119. N. Devlin and D. Parkin (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? a binary choice analysis. Health Econ. 13(5), 437-452.
120. M.F. Drummond and G.W. Torrance (2005) Methods for the Economic Evaluation of Health Care Programmes Oxford: Oxford University Press
121. H.G. Eichler, S.X. Kong, W.C. Gerth, P. Mavros and B. Jonsson (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7(5), 518-528.
122. E. Fenwick, B.J. O’Brien and A.H. Briggs (2004) Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 13 405-415.
123. M. Friedman (1953) Essays in Positive Economics Chicago, IL: University of Chicago Press
124. D. Greenberg, C. Earle, C.H. Fang, A. Eldar-Lissai and P.J. Neumann (2010) When is cancer care cost-effective? a systematic overview of cost-utility analyses in oncology. J. Natl. Cancer Inst. 102(2), 82-88.
125. S. Greenfield and E. Steinberg (2011) Clinical Practice Guidelines We Can Trust Washington, DC: Institute of Medicine, National Academies Press
126. A.L. Hillman and M.S. Kim (1995) Economic decision making in healthcare. A standard approach to discounting health outcomes. Pharmacoeconomics 7(3), 198-205.
127. R. Jain, M. Grabner and E. Onukwugha (2011) Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics 29(4), 297-314.
128. D.A. Katz and H.G. Welch (1993) Discounting in cost-effectiveness analysis of healthcare programmes. Pharmacoeconomics 3(4), 276-285.
129. F.A. Meineke, S. Stäubert, M. Löbe and A.A. Winter (2014) Comprehensive clinical research database based on CDISC ODM and i2b2. Stud. Health Technol. Inform. 205 1115-1119.
130. D. Meltzer (2001) Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J. Health Econ. 20(1), 109-129.
131. P. Muennig (2008) Cost Effectiveness Analysis in Health Care second ed. San Francisco, CA: Jossey-Bass
132. A. O’Hagan, J.W. Stevens and J. Montmartin (2000) Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 17(4), 339-349.
133. D. Petiti (1994) Meta-Analysis, Desicion Analysis, and Cost-Effectiveness Analysis New York, NY: Oxford University Press
134. C.G. Phillips (2005) Health Economics. An introduction for Health Professionals. Massachusetts: Blackwell Publishing Ltd
135. H.U. Prokosch and T. Ganslandt (2009) Perspectives for medical informatics. Reusing the electronic medical record for clinical research. Methods Inf. Med. 48(1), 38-44.
136. F. Shane, G. Loewenstein and T. O’Donoghue (2002) Time discounting and time preference: a critical review. J. Econ. Lit. 40(2), 351-401.
137. D.H. Smith and H. Gravelle (2001) The practice of discounting in economic evaluations of healthcare interventions. Int. J. Technol. Assess. Health Care 17(2), 236-243.
138. A. Towse (2009) Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 338(b181)
139. M. Weinstein and R. Zeckhauser (1973) Critical ratios and efficient allocation. J. Public Econ. 2 147-157.
140. J.L. Yoder (2008) The importance of cost inputs and sensitivity analyses in a cost-effectiveness analysis. Clin. Drug Investig. 28(7), 461-462.
141. J.A. Bock, K.J. Fairley, R.E. Smith, D.D. Maeng, J.M. Pitcavage, N.A. Inverso, et al. (2014) Cost-effectiveness of IL28B genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 17 306-319.
142. D.C. Classen, S.L. Pestotnik, R.S. Evans, J.F. Lloyd and J.P. Burke (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 22(277), 301-306.
143. D.C. Classen, L. Jaser and D.S. Budnitz (2010) Adverse drug events among hospitalized medicare patients: epidemiology and national estimates from a new approach to surveillance. Joint Comm. J. Qual. Patient Saf. 36(1), 12-21.
144. D. Dong, C. Sung and E.A. Finkelstein (2012) Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 79 1259-1267.
145. M.C. Dubinsky, E. Reyes, J. Ofman, C.F. Chiou, S. Wade and W.J. Sandborn (2005) A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100 2239-2247.
146. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet. Med. 11 35-41.
147. FDA Information for Healthcare Professionals: Abacavir (marketed as Ziagen) and Abacavir-Containing Medications. (accessed 31.07.14).
148. J.M. Gudgeon, J.L. Williams, R.W. Burt, W.S. Samowitz, G.L. Snow and M.S. Williams (2011) Lynch syndrome screening implementation: business analysis by a healthcare system. Am. J. Manag. Care 17 e288-e300.
149. J.M. Gudgeon, T.W. Belnap, J.L. Williams and M.S. Williams (2013) Impact of age cutoffs on a Lynch syndrome screening program. J. Oncol. Pract. 9 175-179.
150. C.A. Hughes, M.M. Foisy, N. Dewhurst, N. Higgins, L. Robinson, D.V. Kelly, et al. (2008) Abacavir hypersensitivity reaction: an update. Ann. Pharmacother. 42 387-396.
151. D.A. Hughes, F.J. Vilar, C.C. Ward, A. Alfirevic, B.K. Park and M. Pirmohamed (2004) Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14 335-342.
152. T.L. Kauf, R.A. Farkouh, S.R. Earnshaw, M.E. Watson, P. Maroudas and M.G. Chambers (2010) Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 28 1025-1039.
153. S. Mallal, E. Phillips, G. Carosi, J.M. Molina, C. Workman, J. Tomazic, et al. (2008) PREDICT-1 study team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358 568-579.
154. K. Mitropoulos, L. Johnson, A. Vozikis and G.P. Patrinos (2011) Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol. Drug Int. 26 143-146.
155. Mitropoulou, C., Fragoulakis, V., Bozina, N., Vozikis, A., Supe, S., Bozina, T, et al., Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly croatian patients with atrial fibrillation. In Press 2015.
156. C. Mizzi, C. Mitropoulou, K. Mitropoulos, B. Peters, M.R. Agarwal, R.H. van Schaik, et al. (2014) Personalized pharmacogenomics profiling using whole genome sequencing. Pharmacogenomics 15 1223-1234.
157. M. Mvundura, S.D. Grosse, H. Hampel and G.E. Palomaki (2010) The costeffectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet. Med. 12 93-104.
158. J.J. Ofman, S.D. Sullivan, P.J. Neumann, C.F. Chiou, J.M. Henning, S.W. Wade, et al. (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9 53-61.
159. M.V. Relling, E.E. Gardner, W.J. Sandborn, K. Schmiegelow, C.H. Pui, S.W. Yee, et al. (2011) Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89 387-391.
160. M.V. Relling, E.E. Gardner, W.J. Sandborn, K. Schmiegelow, C.H. Pui, S.W. Yee, et al. (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. Advance online publication 20 February 2013. http://dx.doi.org/10.1038/clpt.2013.4
161. M. Saag, R. Balu, E. Phillips, P. Brachman, C. Martorell, W. Burman, et al. (2008) Study of hypersensitivity to abacavir and pharmacogenetic evaluation study team. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46 1111-1118.
162. R. San Miguel, V. Gimeno-Ballester and J. Mar (2014) Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev. Pharmacoecon Outcomes Res. 14 387-402.
163. B.R. Schackman, C.A. Scott, R.P. Walensky, E. Losina, K.A. Freedberg and P.E. Sax (2008) The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22 2025-2033.
164. S.R. Snyder, C. Mitropoulou, G.P. Patrinos and M.S. Williams (2014) Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision-making in the face of complexity. Public Health Genomics 17 256-264.
165. M.(1) Stanulla, E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, et al. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293 1485-1489.
166. W. Tangamornsuksan, N. Chaiyakunapruk, R. Somkrua, M. Lohitnavy and W. Tassaneeyakul (2013) Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 149 1025-1032.
167. M.E. van den Akker-van Marle, D. Gurwitz, S.B. Detmar, C.M. Enzing, M.M. Hopkins, E. Gutierrez de Mesa, et al. (2006) Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7 783-792.
168. S.R. Alberts, T. Yu, R.J. Behrens, et al. (2013) Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer. J. Clin. Oncol. 31(4), 391.
169. D.A. Asch, J.C. Hershey, M.V. Pauly, J.P. Patton, M.K. Jedrziewski and M.T. Mennuti (1996) Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis. Am. J. Public Health 86(5), 684-690.
170. J.A. Bock, K.J. Fairley, R.E. Smith, D.D. Maeng, J.M. Pitcavage, N.A. Inverso, et al. (2014) Cost-effectiveness of IL28 genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 17 306-319.
171. J. Buchanan, S. Wordsworth and A. Schuh (2013) Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics 14(15), 1833-1847.
172. J.J. Carlson and J.A. Roth (2013) The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res. Treat. 141(1), 13-22.
173. A.B. Caughey (2005) Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns. Gynecol. Obstet. Invest. 60(1), 11-18.
174. R. Conti, D.L. Veenstra, K. Armstrong, L.J. Lesko and S.D. Grosse (2010) Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med. Decis. Making 30(3), 328-340.
175. J. De Leon (2009) Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34(1), 159-172.
176. P.A. Deverka, S.D. Schully, N. Ishibe, J.J. Carlson, A. Freedman, K.A. Goddard, et al. (2012) Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet. Med. 14(7), 656-662.
177. S. Djalalov, Z. Musa, M. Mendelson, K. Siminovitch and J. Hoch (2011) A review of economic evaluations of genetic testing services and interventions (2004–2009). Genet. Med. 13(2), 89-94.
178. H. Fang, X. Liu, J. Ramírez, N. Choudhury, M. Kubo, H.K. Im, et al. (2014) Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J 14 564-572.
179. E. Faulkner, L. Annemans, L. Garrison, M. Helfand, A.P. Holtorf, J. Hornberger, et al. (2012) Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 15(8), 1162-1171.
180. W. Feero, C. Wicklund and D.L. Veenstra (2013) The economics of genomic medicine: insights from the iom roundtable on translating genomic-based research for health. JAMA 309(12), 1235-1236.
181. L.A. Flore and J.M. Milunsky (2012) Updates in the genetic evaluation of the child with global developmental delay or intellectual disability. Semin. Pediatr. Neurol. 19(4), 173-180.
182. M.W. Foster, J.J. Mulvihill and R.R. Sharp (2009) Evaluating the utility of personal genomic information. Genet. Med. 11(8), 570-574.
183. M. Garau, A. Towse, L. Garrison, L. Housman and D. Ossa (2013) Can and should value based pricing be applied to molecular diagnostics? Pers. Med. 10(1), 61-72.
184. L.A. Garraway (2013) Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31(15), 1806-1814.
185. M. Giacomini, F. Miller and B.J. O’Brien (2003) Economic considerations for health insurance coverage of emerging genetic tests. Community Genet. 6(2), 61-73.
186. K.A. Goddard, W.A. Knaus, E. Whitlock, G.H. Lyman, H.S. Feigelson, S.D. Schully, et al. (2012) Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet. Med. 14(7), 633-642.
187. Gordon, A.S., Smith, J.D., Xiang, Q., Metzker, ML., Gibbs, RA., Mardis, ER., et al., PGRNseq: a new sequencing-based platform for high-throughput pharmacogenomic implementation and discovery. Abstract presented at the 62nd Annual Meeting of the American Society of Human Genetics: November 6–8, 2012; San Francisco, CA. Program #244. .
188. S.D. Grosse, L. Kalman and M.J. Khoury (2010) Evaluation of the validity and utility of genetic testing for rare diseases. Adv. Exp. Med. Biol. 686 115-131.
189. S.D. Grosse, C.M. McBride, J.P. Evans and M.J. Khoury (2009) Personal utility and genomic information: look before you leap. Genet. Med. 11(8), 575-576.
190. S.D. Grosse, W.H. Rogowski, L.F. Ross, M.C. Cornel, W.J. Dondorp and M.J. Khoury (2010) Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 13(2), 106-115.
191. S.D. Grosse, S. Wordsworth and K. Payne (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet. Med. 10(9), 648-654.
192. D. Gurwitz, E. Zika, M.M. Hopkins, S. Gaisser and D. Ibarreta (2009) Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12(3), 134-141.
193. G.F. Guzauskas, L.P. Garrison, J. Stock, S. Au, D.L. Doyle and D.L. Veenstra (2013) Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy. Genet. Med. 15(1), 84-87.
194. P.S. Hall, C. McCabe, R.C. Stein and D. Cameron (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J. Natl. Cancer Inst. 104(1), 56-66.
195. S. Holt, G. Bertelli, I. Humphreys, W. Valentine, S. Durrani, D. Pudney, et al. (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. Br. J. Cancer 108(11), 2250-2258.
196. V.W. Hu (2012) Subphenotype-dependent disease markers for diagnosis and personalized treatment of autism spectrum disorders. Dis. Markers. 33(5), 277-288.
197. J. Jarrett and M. Mugford (2006) Genetic health technology and economic evaluation: a critical review. Appl. Health Econ. Health Policy. 5(1), 27-35.
198. K. Kampourakis, E. Vayena, C. Mitropoulou, J. Borg, R.H. van Schaik, D.N. Cooper, et al. (2014) Key challenges for next generation pharmacogenomics. EMBO Rep. 15(5), 472-476.
199. T.L. Kauf, R.A. Farkouh, S.R. Earnshaw, M.E. Watson, P. Maroudas and M.G. Chambers (2010) Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 28(11), 1025-1039.
200. M.J. Khoury, M. Gwinn, W.D. Dotson and M.S. Bowen (2011) Is there a need for PGxceptionalism? Genet. Med. 13(10), 866-867.
201. S.J.L. Knight, C. Yau, R. Clifford, A.T. Timbs, E. Sadighi Akha, H.M. Dréau, et al. (2012) Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 26(7), 1564-1575.
202. I.M. Kopits, C. Chen, J.S. Roberts, W. Uhlmann and R.C. Green (2011) Willingness to pay for genetic testing for Alzheimer’s disease: a measure of personal utility. Genet. Test. Mol. Biomarkers 15(12), 871-875.
203. H. Laduca, A.J. Stuenkel, J.S. Dolinsky, S. Keiles, S. Tandy, T. Pesaran, et al. (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 16 830-837.
204. X. Lin, W. Tang, S. Ahmad, et al. (2012) Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities. Hear. Res. 288(1–2), 67-76.
205. Y. Mai, T. Koromila, A. Sagia, D.N. Cooper, G. Vlachopoulos, G. Lagoumintzis, et al. (2011) A critical view of the general public’s awareness and physicians’ opinion of the trends and potential pitfalls of genetic testing in Greece. Pers. Med. 8(5), 551-561.
206. Y. Mai, C. Mitropoulou, X.E. Papadopoulou, A. Vozikis, D.N. Cooper, R.H. van Schaik, et al. (2014) Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Pers. Med. 11(1), 15-26.
207. A.K. Malhotra, J.P. Zhang and T. Lencz (2012) Pharmacogenetics in psychiatry: translating research into clinical practice. Mol. Psychiatr 17(8), 760-769.
208. E.R. Mardis (2008) The impact of next-generation sequencing technology on genetics. Trends Genet. 24(3), 133-141.
209. L.M. Meckley, J.M. Gudgeon, J.L. Anderson, M.S. Williams and D.L.A. Veenstra (2010) Policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1), 61-74.
210. L. Mette, K. Mitropoulos, A. Vozikis and G.P. Patrinos (2012) Pharmacogenomics and public health: implementing populationalized medicine. Pharmacogenomics 13(7), 803-813.
211. K. Mitropoulos, L. Johnson, A. Vozikis and G.P. Patrinos (2011) Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol. Drug Interact. 26(4), 143-146.
212. C. Mitropoulou, V. Fragoulakis, N. Bozina, A. Vozikis, S. Supe, T. Bozina, et al. (2015) Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly croatian patients with atrial fibrillation. Pharmacogenomics (in press)
213. C. Mizzi, C. Mitropoulou, K. Mitropoulos, B. Peters, M.R. Agarwal, R.H. van Schaik, et al. (2014) Personalized pharmacogenomics profiling using whole genome sequencing. Pharmacogenomics 15 1223-1234.
214. M. Mvundura, S.D. Grosse, H. Hampel and G.E. Palomaki (2010) The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet. Med. 12(2), 93-104.
215. G.P. Patrinos, D.J. Baker, F. Al-Mulla, V. Vasiliou and D.N. Cooper (2013) Genetic tests obtainable through pharmacies: the good, the bad and the ugly. Hum. Genomics 7(1), 17.
216. K. Payne (2007) Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key. Pharmacogenomics 9(1), 1-4.
217. K. Payne (2009) Fish and chips all round? Regulation of DNA-based genetic diagnostics. Health Econ. 18(11), 1233-1236.
218. K. Payne, M. McAllister and L.M. Davies (2012) Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 22(3), 258-271.
219. Recommendations from the EGAPP Working Group: testing for cytochrome P450 (2007) Polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Evaluation of genomic applications in practice and prevention (EGAPP) working group. Genet Med. 9(12), 819-825.
220. T.A. Reydon, K. Kampourakis and G.P. Patrinos (2012) Genetics, genomics and society: the responsibilities of scientists for science communication and education. Pers. Med. 9(6), 633-643.
221. J.S. Roberts, K.D. Christensen and R.C. Green (2011) Using Alzheimer’s disease as a model for genetic risk disclosure: implications for personal genomics. Clin. Genet. 80(5), 407-414.
222. W.H. Rogowski (2007) Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 80(2), 340-357.
223. W.H. Rogowski (2009) The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med. Decis. Making 29(2), 224-238.
224. W.H. Rogowski, S.D. Grosse, J. John, H. Kääriäinen, A. Kent, U. Kristofferson, et al. (2010) Points to consider in assessing and appraising predictive genetic tests. J. Community Genet. 1(4), 185-194.
225. W.H. Rogowski, S.D. Grosse and M.J. Khoury (2009) Challenges of translating genetic tests into clinical and public health practice. Nat. Rev. Genet. 10(7), 489-495.
226. J.A. Roth, L.P. Garrison Jr., W. Burke, S.D. Ramsey, R. Carlson and D.L. Veenstra (2011) Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics 14(2), 59-67.
227. R. Rouzier, P. Pronzato, E. Chéreau, J. Carlson, B. Hunt and W.J. Valentine (2013) Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res. Treat. 139(3), 621-637.
228. C.F. Samer, K.I. Lorenzini, V. Rollason, Y. Daali and J.A. Desmeules (2013) Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther. 17(3), 165-184.
229. S. Sanderson, R. Zimmern, M. Kroese, J. Higgins, C. Patch and J. Emery (2005) How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet. Med. 7(7), 495-500.
230. D.R.J. Singer and J. Watkins (2012) Using companion and coupled diagnostics within strategy to personalize targeted medicines. Pers. Med. 9(7), 751-761.
231. S. Snyder, C. Mitropoulou, G.P. Patrinos and M.S. Williams (2014) Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision-making in the face of complexity. Public Health Genomics 17 256-264.
232. M.E. van den Akker-van Marle, D. Gurwitz, S.B. Detmar, C.M. Enzing, M.M. Hopkins, E. Gutierrez de Mesa, et al. (2006) Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792.
233. T. Van Rooij, D.M. Wilson and S. Marsh (2012) Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Rev. Pharmacoecon. Outcomes Res. 12(3), 289-295.
234. A.L. Vataire, E. Laas, S. Aballea, J. Gligorov, R. Rouzier and E. Chereau (2012) Cost-effectiveness of a chemotherapy predictive test. Bull. Cancer 99(10), 907-914.
235. D.L. Veenstra, M.K. Higashi and K.A. Phillips (2000) Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2(3), E29.
236. S. Wordsworth, J. Buchanan, R. Regan, V. Davison, K. Smith, S. Dyer, et al. (2007) Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the national health service of the United Kingdom. Genomic Med. 1(1–2), 35-45.
237. G.R. Barton, A.H. Briggs and E.A. Fenwick (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11(5), 886-897.
238. S. Birch and A. Gafni (2006) The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J. Health Serv. Res. Policy 11(1), 46-51.
239. J.F. Bridges, E. Onukwugha and C.D. Mullins (2010) Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics 28(3), 175-184.
240. W.S. Cartwright (1999) Methods for the economic evaluation of health care programmes, second edition. By Michael F. Drummond, Bernie O’Brien, Greg L. Stoddart, George W. Torrance. Oxford: Oxford University Press, 1997. J. Ment. Health Policy Econ. 2(1), 43.
241. C. Donaldson, S. Birch and A. Gafni (2002) The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. Health Econ. 11(1), 55-70.
242. C. Donaldson, G. Currie and C. Mitton (2002) Cost effectiveness analysis in health care: contraindications. BMJ 325(7369), 891-894.
243. S. Eckermann, A. Briggs and A.R. Willan (2008) Health technology assessment in the cost-disutility plane. Med. Decis. Making 28(2), 172-181.
244. S. Flessa (2000) Where efficiency saves lives: a linear programme for the optimal allocation of health care resources in developing countries. Health Care Manage. Sci. 3(3), 249-267.
245. A. Gafni (1998) Willingness to pay. What’s in a name? Pharmacoeconomics 14(5), 465-470.
246. A. Gafni and S. Birch (2006) Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med. 62(9), 2091-2100.
247. M. Georgitsi, E. Viennas, V. Gkantouna, E. Christodoulopoulou, Z. Zagoriti, C. Tafrali, et al. (2011) Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics 12(1), 49-58.
248. D. Gyrd-Hansen (2005) Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 23(5), 423-432.
249. M.K. Kvamme, D. Gyrd-Hansen, J.A. Olsen and I.S. Kristiansen (2010) Increasing marginal utility of small increases in life-expectancy? Results from a population survey. J. Health Econ. 29(4), 541-548.
250. C. McCabe, K. Claxton and A.J. Culyer (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26(9), 733-744.
251. A.L. Nelson, J.T. Cohen, D. Greenberg and D.M. Kent (2009) Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann. Intern. Med. 151(9), 662-667.
252. B.J. O’Brien and A.H. Briggs (2002) Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat. Methods Med. Res. 11(6), 455-468.
253. B.J. O’Brien, K. Gertsen, A.R. Willan and L.A. Faulkner (2002) Is there a kink in consumers’ threshold value for cost-effectiveness in health care? Health Econ. 11(2), 175-180.
254. S. Ramsey, R. Willke, A. Briggs, et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 8(5), 521-533.
255. D.L. Schwappach (2002) Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect. 5(3), 210-222.
256. P. Sendi, A. Gafni and S. Birch (2002) Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 11(1), 23-31.
257. P.P. Sendi and A.H. Briggs (2001) Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ. 10(7), 675-680.
258. A.A. Stinnett and A.D. Paltiel (1996) Mathematical programming for the efficient allocation of health care resources. J. Health Econ. 15(5), 641-653.
259. A. Towse (2009) Should NICE’s threshold range for cost per QALY be raised? Yes. BMJ 338 b181.
260. J.E. Veney, P. Williams and T. Hatzell (1997) In search of failure: guidelines for ministries of health. J. Health Popul. Dev. Ctries. 1(1), 1-15.
261. A. Wailoo, A. Tsuchiya and C. McCabe (2009) Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. Pharmacoeconomics 27(12), 983-989.
262. M. Weinstein and R. Zeckhauser (1973) Critical ratios and efficient allocation. J. Public Econ. 2 2147-2157.
263. E.J. Weyler and A. Gandjour (2011) Empirical validation of patient versus population preferences in calculating QALYs. Health Serv. Res
264. S.J. Whitehead and S. Ali (2010) Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull. 96 5-21.
265. X. Yin, J. Goudriaan, E.A. Lantinga, J. Vos and H.J. Spiertz (2003) A flexible sigmoid function of determinate growth. Ann. Bot. 91(3), 361-371.
266. F.L. Zhao, M. Yue, H. Yang, T. Wang, J.H. Wu and S.C. Li (2011) Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making? results from a study in patients with chronic prostatitis. Med. Care 49(3), 267-272.
267. A.C. Berger and S. Olson (2013) The Economics of Genomic Medicine: Workshop Summary Washington, DC: Institute of Medicine of the National Academies, National Academies Press
268. R. Graham, M. Mancher, D. Miller-Wolman, S. Greenfield and E. Steinberg (2011) Clinical Practice Guidelines We Can Trust Washington, DC: Institute of Medicine of the National Academies, National Academies Press
269. J. Knight (2003) Negative results: null and void. Nature 422 554-555.
270. Mitropoulou, C., Fragoulakis, V., Bozina, N., Vozikis, A., Supe, S., Bozina, T., et al., 2015. Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly Croatian patients with atrial fibrillation. Pharmacogenomics.
271. S.R. Snyder, C. Mitropoulou, G.P. Patrinos and M.S. Williams (2014) Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision-making in the face of complexity. Public Health Genomics 17 256-264.